LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

Search

Sana Biotechnology Inc

Deschisă

SectorSănătate

3.23 4.19

Rezumat

Modificarea prețului

24h

Curent

Minim

2.99

Maxim

3.34

Indicatori cheie

By Trading Economics

Venit

-44M

-94M

Marjă de profit

-321.09

Angajați

194

EBITDA

-48M

-95M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+222.58% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

90M

831M

Deschiderea anterioară

-0.96

Închiderea anterioară

3.23

Sentimentul știrilor

By Acuity

50%

50%

167 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

Sana Biotechnology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 sept. 2025, 23:01 UTC

Achiziții, Fuziuni, Preluări

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 sept. 2025, 22:48 UTC

Achiziții, Fuziuni, Preluări

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 sept. 2025, 21:59 UTC

Câștiguri

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 sept. 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

17 sept. 2025, 23:39 UTC

Market Talk

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 sept. 2025, 22:20 UTC

Achiziții, Fuziuni, Preluări

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 sept. 2025, 22:20 UTC

Achiziții, Fuziuni, Preluări

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 sept. 2025, 22:20 UTC

Achiziții, Fuziuni, Preluări

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 sept. 2025, 22:19 UTC

Achiziții, Fuziuni, Preluări

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 sept. 2025, 22:18 UTC

Achiziții, Fuziuni, Preluări

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 sept. 2025, 21:00 UTC

Câștiguri

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 sept. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

17 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 sept. 2025, 19:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 19:59 UTC

Market Talk

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 sept. 2025, 19:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 sept. 2025, 18:43 UTC

Market Talk

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 sept. 2025, 18:38 UTC

Market Talk

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 sept. 2025, 18:20 UTC

Market Talk

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 sept. 2025, 18:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 18:18 UTC

Market Talk

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 sept. 2025, 18:14 UTC

Market Talk

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 sept. 2025, 17:59 UTC

Market Talk

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 sept. 2025, 17:15 UTC

Achiziții, Fuziuni, Preluări

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 sept. 2025, 17:06 UTC

Achiziții, Fuziuni, Preluări

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 sept. 2025, 16:51 UTC

Câștiguri

Correct: Exor 1H Net Loss -EUR624M

17 sept. 2025, 16:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 16:34 UTC

Market Talk

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 sept. 2025, 16:25 UTC

Câștiguri

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 sept. 2025, 16:23 UTC

Câștiguri

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Comparație

Modificare preț

Sana Biotechnology Inc Așteptări

Obiectiv de preț

By TipRanks

222.58% sus

Prognoză pe 12 luni

Medie 10 USD  222.58%

Maxim 12 USD

Minim 5 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSana Biotechnology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

5 ratings

5

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

1.68 / 1.87Suport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

167 / 371 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
help-icon Live chat